NEW YORK, NY - August 14, 2025 (NEWMEDIAWIRE) - By order of the Court dated August 4, 2025 in the action captioned Christiansen v. Spectrum Pharmaceuticals, Inc., Thomas J. Riga and Francois J. Lebel, Case 1:22-cv-10292 (VEC) (S.D.N.Y.) (the “Action”), the Court has reopened the lead plaintiff appointment process.

Members of the putative class may move the Court to serve as substitute lead plaintiff not later than Wednesday, September 24, 2025.

Members of the putative class may view the operative complaint and the Court’s decision on the motion to dismiss here. Previously, the Court appointed Kaplan Fox & Kilsheimer LLP to serve as Lead Counsel.

The Action has been pending since 2022, and after substantial discovery and motion practice, the Action currently alleges violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against Spectrum Pharmaceuticals, Inc., Thomas J. Riga and Francois J. Lebel on behalf of purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period May 12, 2022 through September 22, 2022 for allegedly making false or misleading statements about a drug manufactured by Spectrum Pharmaceuticals, Inc.

Shares of Spectrum Pharmaceuticals, Inc. traded on Nasdaq under the symbol SPPI. In July 2023, Assertio Holdings, Inc. (Nasdaq: ASRT) closed its acquisition of Spectrum Pharmaceuticals, Inc.

If you have any questions about this Notice, the Action, your rights, or your interests, please e-mail attorney Jeffrey P. Campisi (jcampisi@kaplanfox.com) or contact him by phone, regular mail, or fax, or click here.

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
Telephone: (212) 329-8571
Fax: (212) 687-7714
Website: www.kaplanfox.com
E-mail: jcampisi@kaplanfox.com

View the original release on www.newmediawire.com